TrialInternational journal of clinical oncology2022

First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.

Shunji Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.